Novartis Ireland Limited

Lobbying Organisation Novartis Ireland Limited

Date published 08 Jan, 2026

Relevant Matter Matters involving public funds

Public Policy Area Health

Period 1 Sep, 2025 to 31 Dec, 2025

Specific Details Implement the decision to include SMA screening implemented in the heelprick test for newborn babies

Intended results SMA screening implemented in the heelprick test for newborn babies

Name of person primarily responsible for lobbying on this activity Jonathan OGrady, CEO SMA Ireland

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Mass communications

Email All TDs Three emails asking for the HSE to implement the Nov 22 decision to add SMA to the heelprick test for newborns referencing 1)the launch of the rare disease strategy 2)the launch of the Innovate for Life campaign with families with SMA 3)open letter from SMA Europe on international comparisons (80% of babies in Europe already screened for SMA but not in Ireland).

Email All Senators Three emails asking for the HSE to implement the Nov 22 decision to add SMA to the heelprick test for newborns referencing 1)the launch of the rare disease strategy 2)the launch of the Innovate for Life campaign with families with SMA 3)open letter from SMA Europe on international comparisons (80% of babies in Europe already screened for SMA but not in Ireland).

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

Three emails asking for the HSE to implement the Nov 22 decision to add SMA to the heelprick test for newborns referencing 1)the launch of the rare disease strategy 2)the launch of the Innovate for Life campaign with families with SMA 3)open letter from SMA Europe on international comparisons (80% of babies in Europe already screened for SMA but not in Ireland).

Designated public officials lobbied

There were no DPOs directly lobbied during this return period on this specific Subject Matter Area.